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Introduction: Primary chest wall sarcomas are rare mesenchymal
tumors and their mainstay of therapy is wide surgical resection. We
report our single-institution, multidisciplinary experience with full-
thickness resection for primary chest wall sarcomas.
Methods: A retrospective review of our prospectively maintained
databases revealed that 51 patients were referred for primary chest
wall sarcomas from 1990 to 2009.
Results: All patients required resections that included rib and/or
sternum. Twenty-nine patients (57%) had extended resections be-
yond the chest wall. Forty-two patients (82%) required prosthetic
reconstruction and 17 patients (33%) had muscle flap coverage.
Overall, 51% (26/51) of patients received neoadjuvant therapy.
Seventy-three percent (11/15) of high-grade soft tissue sarcomas,
77% (10/13) of high-risk bony sarcomas, and 67% (4/6) of desmoid
tumors were treated with induction therapy. Negative margins were
obtained in 46 patients (90%). There were no perioperative mortal-
ities. Eight patients (16%) experienced complications. Local recur-
rence and metastasis was detected in 14 and 23%. Five-year overall
and disease-free survivals were 66% and 47%, respectively. Favor-
able prognostic variables for survival included age50 years, tumor
volume 200 cm3, desmoid tumor, bony tumor, chondrosarcoma,
and low-grade soft tissue sarcoma.
Conclusions: We report our multidisciplinary experience with pri-
mary chest wall sarcomas that included induction therapy in the
majority of high-risk soft tissue and bony sarcomas and desmoid
tumors. Despite aggressive preoperative treatments, acceptable sur-
gical results with low morbidity and mortality can be achieved.
Neoadjuvant systemic therapy may reduce local and distant recur-
rence and improve overall survival.
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Sarcomas are rare mesenchymal tumors that comprise lessthan 1% of all adult malignancies and arise from the chest
wall in less than 20% of all sarcoma cases.1–5 Many histo-
logical subtypes have been identified, which are broadly
divided into soft tissue or bony types. In the United States,
there are approximately 7000 cases of soft tissue and 2500
bony sarcomas reported per year.6 Wide surgical resection
with margin negativity is the mainstay of therapy. Pros-
thetic reconstruction and soft tissue coverage is often
required after full-thickness chest wall resection to main-
tain chest wall stability, prevent flail chest, and preserve
pulmonary function.
Although surgical resection has been the standard treat-
ment of soft tissue and bony sarcomas, the impact of chemo-
therapy and/or radiation on more aggressive tumors remains
unclear. It is generally well accepted that histology and grade
are important factors in determining the need for multimo-
dality treatment. Although certain bony sarcomas, such as
osteosarcoma or Ewing sarcoma, have accepted and estab-
lished roles for chemotherapy and radiation, the application
of multimodality approaches particularly for soft tissue sar-
comas is an evolving field of investigation and remains
controversial.
We report our single-institution, multidisciplinary ex-
perience with (1) primary chest wall sarcomas followed by
full-thickness chest wall resection and reconstruction and (2)
a subset analysis of patients who received induction therapy
for high-risk sarcomas. Neoadjuvant therapy (chemotherapy
or chemoradiation) was used in cases of high-grade soft tissue
sarcomas, high-risk bony sarcomas (i.e., osteosarcoma, Ew-
ing, and mesenchymal or dedifferentiated chondrosarcomas),
and desmoid tumors. Desmoid tumors were considered with
low-grade sarcomas in this study due to their aggressive local
behavior resulting in significant morbidity, and those involv-
ing the chest wall and adjacent structures are associated with
a high recurrence rate despite resection with margin negativ-
ity.7 There is a growing body of evidence to support the use
of neoadjuvant therapies before surgical resection with asso-
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ciated improved outcomes, particularly in situations where
surgery results in morbidity with high risk for recurrence.8,9
We evaluated patient and tumor characteristics, morbidity,
mortality, and outcome data to identify prognostic factors that
impact overall and disease-free survival after application of
our institutional algorithm that incorporated the use of induc-
tion therapy, where applicable.
PATIENTS AND METHODS
Fifty-one patients were referred to the David Geffen
School of Medicine at University of California, Los Angeles
(UCLA), with primary chest wall musculoskeletal tumors
from 1990 to 2009. Patients were considered for this analysis
if they carried a diagnosis of a primary chest wall sarcoma
and underwent a full-thickness chest wall resection and re-
construction. Chest wall neoplasm was defined as any neo-
plasm involving the ribs or sternum. A retrospective review
of our prospectively maintained sarcoma databases was per-
formed to identify appropriate patients. Clinical data were
obtained from medical records following Institutional Review
Board approval.
Histological review was performed by dedicated mus-
culoskeletal pathologists to determine histology (soft tissue
versus bony), grade, and margin status. Soft tissue sarcomas
were graded using the French Federation of Cancer Centers
Sarcoma Group grading system, and bony sarcomas were
classified as grade 1, 2, or 3 as per convention.
A multidisciplinary musculoskeletal tumor board eval-
uated patients pre- and postoperatively to determine the
appropriateness of neoadjuvant and adjuvant treatments. All
patients were considered for multimodality therapy that in-
cluded the use of induction therapy (chemotherapy, radiation,
or chemoradiation) followed by full-thickness chest wall
resection and reconstruction for primary sarcomas. Neoadju-
vant therapy was considered in subjects with high-risk sar-
comas: (1) high-grade soft tissue sarcomas, (2) high-risk
bony sarcomas (osteosarcoma, Ewing sarcoma, and mesen-
chymal or dedifferentiated chondrosarcoma), and (3) a subset
of desmoid tumors (Figure 1). All patients underwent full-
thickness chest wall resection with ribs or sternum with the
intent for complete resection with wide margins that included
a rib above and below the tumor. Mesh reconstruction was
performed with the following materials: Prolene (Ethicon,
Inc., Somerville, NJ), polytetrafluoroethylene (Gore-Tex;
W.L. Gore & Associates, Inc., Flagstaff, AZ), methylmeth-
acrylate (Stryker Howmedica Osteonics, Mahway, NJ), or
Marlex (Bard Davol, Cranston, RI). Soft tissue coverage,
when required, was achieved with pedicled or free myocuta-
neous flaps. Local recurrence was defined as appearance of
sarcoma in the site of previous resection. Metastasis was
defined as appearance of sarcoma outside of the chest wall
resection area.
The Kaplan-Meier method was used to calculate overall
and disease-free survival probabilities. All survival and re-
currence data were calculated from the date of surgical
resection. Differences in overall and disease-free survival
were determined by log-rank analysis. The following vari-
ables were evaluated for prognostic significance: age, gender,
tumor volume, histology (soft tissue versus bony), grade,
extent of resection, margin status, neoadjuvant therapy, and
adjuvant treatments. Significance was defined as p  0.05.
RESULTS
Patient and Clinical Presentation
Fifty-one patients with primary chest wall sarcomas
underwent wide surgical extirpation, and of these, six patients
referred from outside institutions presented with a recurrent
chest wall sarcoma. Patient characteristics are described in
Table 1. There were 24 males (47%) and 27 females (53%)
with an average age of 50.9 years. Most patients were
symptomatic with the most common symptom being pain
(41%) and examination finding a palpable mass (33%). Ten
patients (20%) had a history of chest wall irradiation for
treatment of lymphoma or breast carcinoma with a median of
10 years (range, 4–17 years) until the development of their
chest wall sarcomas.
Tumor Characteristics
The resected chest wall tumors were evaluated for size
and grade (Table 1). Three patients had a complete response
to neoadjuvant therapy accounting for immeasurable disease.
The average tumor diameter, cross-sectional area, and vol-
umes were 8.7 cm, 81.6 cm2, and 611.5 cm3, respectively.
There was nearly equal distribution of tumor grade between
low- or intermediate-grade (49%) and high-grade (51%) sar-
comas. Histological subtypes of the resected chest wall sar-
comas are described in Table 2. Bony versus soft tissue
histological subtypes were evenly distributed (49% versus
51%). Bony sarcomas included chondrosarcoma, Ewing sar-
coma, or osteosarcoma. There were six (12%) desmoid tu-
mors in our study.
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FIGURE 1. Flow chart of the treatment algorithm for chest
wall sarcomas at University of California, Los Angeles
(UCLA). Number of patients in each group is indicated next
to the arrows. , Four patients with desmoid tumors and
one patient with leiomyosarcoma received induction ther-
apy. , Induction therapy data were not available for one
patient with chondrosarcoma.
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Neoadjuvant and Adjuvant Therapy
Diagnosis was obtained in 44 patients (86%) via image-
guided core needle (39%; 17/44) or incisional surgical biopsy
(61%; 27/44) before definitive resection of their primary
chest wall sarcomas. Six patients proceeded directly to sur-
gical resection after a chest wall tumor was identified. Twe-
nty-six patients (51%) received neoadjuvant treatment (che-
motherapy, radiation, or hormonal therapy) after the biopsies
were reviewed in a multidisciplinary musculoskeletal tumor
board (Figure 1 and Table 3). Patients received various
chemotherapy regimens preoperatively (Table 3). Combined
chemoradiation with a dose range of 45 to 60 Gy was given
to patients with high-grade soft tissue sarcomas. Osteosarco-
mas and dedifferentiated or mesenchymal chondrosarcomas
were treated with chemotherapy alone. Ewing sarcomas were
treated with combined chemoradiation or chemotherapy
alone. Desmoid tumors were treated with several investiga-
tional systemic therapies and/or radiation. Seventy-three per-
cent (11/15) of high-grade soft tissue sarcomas, 77% (10/13)
of high-risk bony sarcomas, and 67% (4/6) of desmoid
tumors were treated with induction therapy (Figure 1). In
general, patients with low-grade soft tissue sarcomas and
conventional chondrosarcomas were resected without induc-
tion therapy. However, five patients with low- or intermedi-
ate-grade sarcomas received induction therapy for which four
patients had desmoid tumors (Figure 1). In contrast, the
majority of patients (61%; 31/51) did not receive adjuvant
chemotherapy or radiotherapy.
Chest Wall Resection and Reconstruction
Surgical removal in all patients required full-thickness
chest wall resection that included rib or sternum. The details
of surgical resection and reconstruction are described in
Table 3. An average number of 3.7 ribs were resected.
Twenty-two patients (43%) had only ribs, only sternum, or
both resected, whereas the remaining 29 patients (57%) had
extended resections beyond just the chest wall (Table 3). A
total of 12 patients (24%) required partial or complete ster-
nectomies, including 7 patients from the extended resections
group. Local extension from the chest wall sarcoma into other
structures was not a contraindication to resection. The lung
was most commonly involved in 14 patients (27%).
Forty-two patients (82%) required prosthetic recon-
struction of chest wall defects. The types of mesh used
include Prolene, polytetrafluoroethylene, or Marlex alone or
in combination with methylmethacrylate (Table 3). Soft tis-
sue coverage was required in 17 patients (33%).
Margin Status
Negative margins (R0 resection) were obtained in 46
patients (90%), whereas the remaining 5 patients (10%) had
a microscopically positive margin (R1 resection; Table 3).
There were no patients who underwent a grossly margin
positive (R2) resection.
Complications and Hospital Course
There were no 30-day perioperative or hospital mortal-
ities (Table 3). Eight patients (16%) experienced complica-
tions postoperatively. Surgical site infections developed in
TABLE 2. Histological Subtypes of Chest Wall Sarcomas
No. of Tumors (n  51)
Chondrosarcomaa 15
Ewing sarcoma/PNET 8
Radiation-associated sarcoma 6
Desmoid tumor 6
Angiosarcoma 3
Osteosarcoma 3
Dedifferentiated liposarcoma 2
Leiomyosarcoma 2
Fibrosarcoma 1
Granular cell tumor 1
Giant cell tumor 1
High-grade sarcoma NOSb 1
Myxofibrosarcoma 1
Synovial sarcoma 1
a13 conventional, 1 dedifferentiated, and 1 mesenchymal chondrosarcomas.
bPreviously known as malignant fibrous histiocytoma.
PNET, primitive neuroectodermal tumor; NOS, not otherwise specified.
TABLE 1. Patient and Tumor Characteristics (Total
Patients  51)
N %
Age (yr)
Average 50.9
Range 17–90
Sex
Male 24 47
Female 27 53
Symptoms
Pain 19 37
Palpable mass 17 33
Asymptomatic 3 6
Dyspnea and pain 2 4
Dyspnea 1 2
Weight loss 1 2
Unknown 8 16
History of chest wall XRT
Yes 10 20
No 39 76
Unknown 2 4
Tumor dimensions
Average diametera 8.7 cm
Diameter rangeb 1.5–29.5 cm
Average volumec 611.5 cm3
Volume rangeb 1.5–6372 cm3
Tumor grade
Low/intermediate 25 49
High 26 51
aTumor diameter data was not available for two patients.
bThree patients had a complete response after neoadjuvant therapy resulting in
immeasurable disease in final specimen.
cTumor volume data were not available for seven patients.
XRT, radiotherapy.
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two patients (4%) who required surgical debridement with
mesh removal, and one patient had a revision of her muscle
flap. One patient (2%) had a wound dehiscence that required
subsequent reoperation and mesh removal. All three patients
who experienced local wound issues had prior radiation. Of
these, two patients had previous history of breast cancer and
received 50 Gy radiation remotely, and one patient received
induction chemoradiation (unknown dose) just before surgi-
cal resection of the chest wall sarcoma.
Complications from a fungal pneumonia in one patient
(2%) led to respiratory failure requiring a tracheostomy, but
the patient was decannulated before hospital discharge. After
developing an empyema, one patient (2%) underwent tube
drainage as well as surgical debridement and mesh removal.
One patient (2%) required full-thickness chest wall resection
with four ribs as well as extended resection involving the
diaphragm, sigmoid colon, and spleen due to a combined
chest wall and retroperitoneal sarcoma. He developed both a
massive air leak after inadvertent injury to the left lower lobe
that required a wedge resection and a pancreatic leak that was
managed nonoperatively with drainage catheters. One patient
(2%) had a history of chest wall radiation and prior sarcoma
resection and developed disseminated intravascular coagula-
tion during resection of the chest wall tumor infiltrating the
lung and failure of a free myocutaneous flap. She recovered
well after supportive therapy in the intensive care unit but
required revision with a second free myocutaneous flap. On
postoperative day 4, one patient (2%) had atrial fibrillation
with immediate conversion to normal sinus rhythm and was
controlled with antiarrhythmic medications. The median
length of hospital stay for all patients was 6 days.
Recurrence and Metastasis
Twenty-four patients (47%) had no documented re-
currences at the time of last follow-up (Table 3). Eight
patients (16%) did not receive follow-up care at UCLA
TABLE 3. Clinical Characteristics, Surgical Resection, and
Multimodality Treatments
No. of Patients (n  51) %
Chest wall resection
Average number of ribsa 3.7
Range of ribs 1–10
Ribs only 17 33
Sternum only 2 4
Sternum and ribs only 3 6
Extended resectionb 29 57
Extended resection
Lung 14 27
Diaphragm 6 12
Clavicle/scapula 5 10
Vertebrae 3 6
Pericardium 2 4
Adventitia of descending aorta 1 2
Brachial plexus 1 2
Otherc 6 12
Reconstruction
Mesh only 24 47
MMAd  mesh 18 35
No mesh 7 14
Unknown 2 4
Muscle flap
Pedicled 14 27
Free 3 6
Neoadjuvant therapy
Chemotherapy 14 27
Chemo/radiotherapy 10 20
Hormonal therapy 1 2
Hormonal/radiotherapy 1 2
None 24 47
Unknown 1 2
Adjuvant therapy
Chemotherapy 11 21
Radiotherapy 6 12
None 31 61
Unknown 3 6
Chemotherapy regimens 24 47
Doxorubicin  ifosfamide 12 23
Ifosfamide 4 8
Gemcitabine  docetaxel 3 6
Doxorubicin 2 4
Methotrexate 2 4
Unknown 1 2
Margin status
Negative/R0 46 90
Positive
R1 5 10
R2 0 0
Complications
Mortality (30 d) 0 0
None 41 80
Surgical site infection 2 4
Wound dehiscence 1 2
Pneumonia/respiratory failure 1 2
Empyema 1 2
Massive air leak/pancreatic leak 1 2
DIC/failed free muscle flap 1 2
Arrhythmia 1 2
Unknown 2 4
Hospitalization
Median number of days 6
Range of days 2–36
Unknown 3 6
Outcome
No recurrence 24 47
Local recurrence 7 14
Lung metastases 11 21
Bone metastases 1 2
Unknown 8 16
aThe number of ribs resected data was not available for one patient.
bSeven patients with extended resections also required either partial or complete
sternectomy.
cOther resections included the following: breast/pectoralis muscle/lymph nodes (1),
abdominal wall (2), liver (1), sigmoid colon (1), and spleen (1).
dMethylmethacrylate was supplied by Stryker Howmedica Osteonics, Mahway, NJ.
MMA, methylmethacrylate; DIC, disseminated intravascular coagulation.
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after initial perioperative care. Local recurrence and me-
tastasis was detected in 14% and 23%, respectively. A total
of 16 patients (31%) received preoperative or postopera-
tive radiation therapy, and of these, 2 patients developed a
local recurrence. One patient received both neoadjuvant
and adjuvant radiation.
Of the seven patients (14%) with a local recurrence,
four had low-grade and three had high-grade sarcomas. None
of the seven patients received adjuvant radiation. However,
two of these patients received induction radiation. Only one
of the seven patients had a microscopically positive (R1)
resection margin.
The most common site of metastasis was the lung
(21%). One patient (2%) who presented with a local recur-
rence after initial chest wall resection had a synchronous lung
metastasis. All other patients had no evidence of metastasis at
the time of chest wall resection.
Overall Survival and Disease-Free Survival
The 5-year overall survival and disease-free survival
after surgical resection of primary chest wall sarcomas for
variables that included age, gender, tumor volume, histology
(bony and soft tissue origins), extended or sternal resection,
margin status, and neoadjuvant and adjuvant therapy are
described in Table 4. The 5-year overall survival and disease-
free survival for all patients (soft tissue and bony sarcomas)
were 66% and 47%, respectively (Figure 2). Table 4 de-
scribes favorable prognostic variables for 5-year overall sur-
vival which included age 50 years, tumor volume 200
cm3, desmoid tumor, bony tumor, chondrosarcoma, and low-
grade soft tissue sarcoma. Favorable prognostic factors for
disease-free survival included chondrosarcoma and low-
grade soft tissue sarcoma. The need for extended or sternal
resections did not portend a worse survival or recurrence
outcome. Negative margin status in chest wall sarcomas,
excluding desmoids, showed improved survival (63% versus
25% 5-year survival) but did not achieve statistical signifi-
cance presumably due to the limited number of resections
with positive microscopic margins (four patients; Table 4).
The survival outcomes did not change significantly with
inclusion of desmoid tumors (data not shown).
DISCUSSION
Although wide surgical resection is the established
standard treatment for all sarcomas, approximately 50% of
patients with high-risk soft tissue sarcomas will develop
metastatic disease despite optimal local treatment with the
majority occurring within 2 years of surgical resection and
ultimately succumbing to their disease.10 Presumably, many
of these patients have micrometastatic disease at presentation.
Once macroscopic metastatic disease is evident, the median
survival is 11.7 months.11 Although certain bony sarcomas,
such as osteosarcoma or Ewing sarcoma, have accepted and
FIGURE 2. Outcome of all patients with bony and soft tis-
sue sarcomas. The 5-year overall survival (OS) of all patients
is 66%. The 5-year disease-free survival (DFS) is 47%.
TABLE 4. Survival and Disease-Free Interval Data after
Chest Wall Resection
N
5-yr
Survival
(%)
Log-rank
p
5-yr
Disease-Free
Survival (%)
Log-rank
p
Age
50 yr 26 76 0.004 64 NS
50 yr 25 50 32
Gender
Male 24 65 NS 38 NS
Female 27 61 60
Tumor volume
200 cm3 23 75 0.04 31 NS
200 cm3 21 51 72
Histology
Bony 26 67 0.02 42 NS
Soft tissue 19 46 34
Desmoid 6 100 100
Bony
Chondrosarcoma 15 85 0.02 42 0.03
Ewing/PNET 8 63 60
Osteosarcoma 3 0 0
Soft tissue
Low-grade 4 67 0.04 100 0.03
High-grade 15 43 22
Desmoid 6 100 100
Extended resection
Yes 36 55 NS 41 NS
No 15 79 61
Sternal resection
Yes 12 75 NS 65 NS
No 39 58 41
Margin status (excluding desmoids)
Positive (R1) 4 25 NS 50 NS
Negative (R0) 41 63 39
Neoadjuvant therapy
Yes 26 49 NS 34 NS
No 24 76 60
Adjuvant therapy
Yes 17 54 NS 25 NS
No 31 66 61
NS, not significant; PNET, primitive neuroectodermal tumor.
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established roles for chemotherapy and radiation, the appli-
cation of multimodality treatments for soft tissue sarcomas
remains controversial. Doxorubicin, dacarbazine, and ifosf-
amide have consistently been associated with response rates
of about 20% or more in high-grade soft tissue sarcomas.12
Response rates to high-dose ifosfamide or in combination
with doxorubicin have shown more favorable response rates
of 20 to 60% in some series.12–17 However, despite extensive
research, there is still no clear answer as to whether adjuvant
or neoadjuvant chemotherapy can improve survival in pa-
tients with soft tissue sarcomas.
There have been many reports in the literature describ-
ing the experience with surgical resection of primary or
recurrent chest wall sarcomas.2–5,18–21 The majority of these
studies, however, did not involve or describe the impact of
neoadjuvant therapy on surgical resection. Herein, we report
our multidisciplinary approach to primary chest wall sarco-
mas involving full-thickness chest wall resection and recon-
struction and describe our results of resection after induction
therapy for high-risk sarcomas. Neoadjuvant therapy (chemo-
therapy or chemoradiation) was given for high-grade soft
tissue sarcomas, high-risk bony sarcomas (i.e., osteosarcoma,
Ewing, and mesenchymal or dedifferentiated chondrosarco-
mas), and desmoid tumors. Desmoid tumors were grouped
with low-grade sarcomas due to their aggressive local behav-
ior and associated significant morbidity, and thus investiga-
tional agents were considered before surgical resection.
Although neither this study nor others have directly
addressed whether neoadjuvant or adjuvant therapy is more
efficacious for primary chest wall sarcomas, there are some
clear advantages to induction therapy, which include (1)
tumor volume reduction and increased tumor necrosis with
improved likelihood of complete resection, (2) immediate
systemic therapy for micrometastatic disease, and (3) patho-
logic evaluation of effectiveness of preoperative therapy after
surgical resection. It is on this basis that our institutional
preference is preoperative therapy whenever applicable.
In our series, 73% of high-grade soft tissue sarcomas,
77% of high-risk bony sarcomas, and 67% of desmoid tumors
were treated with induction therapy. Overall, 51% of patients
received neoadjuvant treatment (chemotherapy, radiation, or
hormonal therapy) before surgical resection. Our algorithmic
approach resulted in a substantially higher percentage of
patients receiving induction therapy compared with other
series where 0 to 27% of patients received preoperative
systemic treatment, with the exception of the Walsh et al.
study in which similarly 51% of patients with soft tissue or
bony sarcomas received preoperative therapy.4,5,18–21 Despite
the relatively high percentage of patients undergoing induc-
tion therapy, complete resection was achieved in the majority
of our patients with a 16% complication rate and no 30-day
postoperative mortality. Our morbidity and mortality rates are
comparable to other reports of 13 to 24% and 0 to 1.7%,
respectively, in which only a minority of patients underwent
initial induction treatment.2–5,18–21 As such, preoperative ther-
apy does not seem to increase morbidity or mortality associ-
ated with chest wall resections at our institution.
Combined chemoradiation was given in patients with
high-grade soft tissue sarcomas and certain bony sarcomas
(i.e., Ewing sarcoma) preoperatively. Despite the utilization
of radiation in these instances, we experienced acceptable
wound complication rates (4% infection and 2% dehiscence).
Interestingly, all three patients who experienced local wound
issues had prior radiation. Two patients had received 50 Gy
radiation remotely for breast cancer, and one patient received
induction chemoradiation (unknown dose) just before surgi-
cal resection. In a prospective randomized trial, O’Sullivan et
al. 22 reported more frequent wound complications in patients
with soft tissue sarcomas of the extremity that received
preoperative (35%) compared with postoperative (17%) ra-
diation with a preoperative radiation dose of 50 Gy. In this
study, when radiation was used preoperatively with chemo-
therapy, the dose range was 45 to 60 Gy. However, in our
more recent experience, we have limited the radiation dose to
TABLE 5. Publications of Primary Chest Wall Sarcoma Experience (2000–2011)
Author (yr) Patients
Sarcoma
Type
High-Grade
Sarcomas Morbidity
30-d
Mortality
Recurrence
5-yr
OS
5-yr
DFS
Neoadjuvant
Therapy
Adjuvant
Therapy
Local Distant C-XRT C XRT C-XRT C XRT
Our
Study (2011)
51 STS/bone 51% 16% 0% 14% 23% 66% 47% 22% 29% 0% 0% 21% 12%
van Geel
et al. (2010)
60 STS/bone 63% 22% 1.7% 33% 48% 46% 30% 0% 0% 0% 0% 0% 27%
Tsukushi
et al. (2009)
44 STS 50% Unk Unk 11% 7% 89% 89% Unk Unk Unk 0% 9% 9%
Wouters
et al. (2008)
83 STS/bone 38% 20% 0% 41%a 58%a 63% Unk 0% 20% 2% 0% 17% 30%
Pfannschmidt
et al. (2006)
25 STS 52% 0% 0% 36% 56% 57% Unk 0% 4% 4% 0% 12% 8%
Gross
et al. (2005)
55 STS 42% Unk Unk 11% 18% 87% 75% 27% 0% 0% 0% 0% 4%
Walsh
et al. (2001)
51 STS/bone 53% 24% 0% 18% 24% 64% 54% 2% 43% 6% 8% 18% 0%
OS, overall survival; DFS, disease-free survival; C-XRT, chemoradiation; C, chemotherapy; XRT, radiation therapy; STS, soft tissue sarcoma; Unk, unknown.
aRefers to the entire primary chest wall sarcoma group with no specification to neoadjuvant or adjuvant therapy.
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45 Gy in the preoperative setting to prevent local wound
issues, and muscle flap reconstruction of the chest wall is
universally performed in the setting of preoperative radiation
or remote history of radiation in the field of chest wall
resection. The application of muscle flaps is likely to have
reduced local wound complications and contributed to the
overall acceptable morbidity and no mortality in our study.
In reviewing the literature of studies published since
2000 that adequately described multimodality treatments, the
incorporation of neoadjuvant systemic therapy before surgi-
cal resection of primary chest wall sarcomas seems to have
more favorable long-term outcome with respect to local and
distant recurrence (Table 5). In this study, 51% of patients
with soft tissue or bony sarcomas received induction systemic
therapy with a local recurrence of 14% and distant recurrence
of 23%. These findings are similar to the studies from Walsh
et al. and Gross et al.4,19 In contrast, studies that did not
incorporate systemic therapy in a multimodality fashion with
surgery had poorer outcomes with respect to recurrence.5,18,21
The use of adjuvant radiation did not seem to have a clear
relationship with local recurrence.4,5,18–21 In most series,
postoperative radiation was given in up to 9% of patients
(Table 5). However, van Geel et al. and Wouters et al.
described the utilization of adjuvant radiation in 27% and
30% of patients, but they still reported relatively high overall
local recurrence rates of 33% and 41%, respectively.5,18 The
overall survival seems to be more favorable in series that
incorporated the use of systemic therapy. Our survival results
were comparable with the survival ranges in the published
literature where neoadjuvant systemic therapy was used (63–
87%).4,5,19,21 Thus, the use of systemic therapy in high-risk
sarcomas may contribute to improved overall survival. How-
ever, it remains unclear whether neoadjuvant or adjuvant
chemotherapy is more effective.
In summary, we report our multidisciplinary approach
and experience with treatment of primary chest wall sarcomas
and the application of induction therapies in high-risk soft
tissue and bony sarcomas. A multidisciplinary discussion
before treatment initiation is required for optimal therapy.
Despite aggressive preoperative treatments, acceptable surgi-
cal results and long-term outcomes can be achieved with
complex, full-thickness chest wall resections and reconstruc-
tions. Multispecialty teams may be required for more com-
plex operations. Extended resections beyond the chest wall
was not associated with worse outcome. The use of neoad-
juvant systemic therapy in primary chest wall sarcomas
seems to portend a more favorable long-term outcome but
warrants further exploration and validation.
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